Things we have learned from tilapia islet xenotransplantation.
An islet xenotransplantation model has been developed using tilapia (Oreochromis niloticus) as the donors. Studies using this model for the treatment of experimental type 1 diabetes in mice have produced promising results including the maintenance of long-term normoglycemia and mammalian-like glucose tolerance profiles in islet graft recipients. Islet encapsulation has also provided a promising method for the prevention of graft rejection, and strains of transgenic tilapia expressing a [desThrB30] human insulin molecule have been produced. In addition to studying islet transplantation for the treatment of type 1 diabetes, these studies have also produced insights into piscine glucose homeostasis. Studies demonstrating the glucose responsiveness of tilapia islets are described. In addition, work performed by our group and by others pertaining to presence and nature of piscine glucose transporters is reviewed. Finally, studies addressing some of the broader challenges of islet xenotransplantation are discussed with particular attention paid to the post-transplantation fate of the various islet cell populations and the proteins they produce.
Alexander
Emily L R
EL
Department of Pathology and Laboratory Medicine, IWK Health Centre and Dalhousie University, Halifax, NS, Canada.
Dooley
Kent C
KC
Pohajdak
Bill
B
Xu
Bao-You
BY
Wright
James R
JR
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D004703:Endocrine System / Q000502:physiology; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000502:physiology*; D017210:Tilapia / Q000502:physiology* / Q000601:surgery*; D014183:Transplantation, Heterologous / Q000502:physiology* / Q000662:veterinary*